Intuitive Machines vs Moderna, Inc. — how do they compare? Intuitive Machines trades at $13.19 (market cap $2.21B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 35.6× Intuitive Machines's market cap, and Moderna, Inc. is trading nearer its 52-week high, Intuitive Machines nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Intuitive Machines for 5 Days and Moderna, Inc. for 59 Days on average.
| LUNR | MRNA | |
|---|---|---|
Market Cap | $2.21B | $78.65B |
Volume | 9,284,614 | 37,373,437 |
Sector | Industrials | Health |
52-Week High | $45.70 | $203.46 |
52-Week Low | $8.05 | $22.36 |
Typical Hold Time | 5 Days | 59 Days |
Enterprise Value | $2.28B | $74.80B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Intuitive Machines provides lunar access, data, and infrastructure services. Its capabilities include lunar landers, communications systems, and technologies designed to support missions to the Moon.
Read more on LUNR →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →